Coverage
-
August 22, 2019
In light of a recent Federal Circuit decision, Amgen Inc. can no longer allege that Mylan Inc.'s proposed Neulasta biosimilar infringed one of its patents, a Pennsylvania federal court ruled Wednesday, granting a joint request from both parties to nix the claim.
2 other articles on this case.
View all »